Bulletin
Investor Alert

Bayer AG ADR

OTC: BAYRY

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

Aug 7, 2020, 3:59 p.m.

/zigman2/quotes/203424967/delayed

$

16.46

Change

-0.16 -0.96%

Volume

Volume 648,446

Quotes are delayed by 20 min

/zigman2/quotes/203424967/delayed

Previous close

$ 16.62

$ 16.46

Change

-0.16 -0.96%

Day low

Day high

$16.31

$16.49

Open

52 week low

52 week high

$12.78

$21.49

Open

Company Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in...

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Valuation

P/E Current

13.43

P/E Ratio (without extraordinary items)

17.47

Price to Sales Ratio

1.64

Price to Book Ratio

1.51

Price to Cash Flow Ratio

10.41

Enterprise Value to EBITDA

11.75

Enterprise Value to Sales

2.42

Total Debt to Enterprise Value

0.37

Efficiency

Revenue/Employee

419,412.00

Income Per Employee

23,222.00

Receivables Turnover

3.09

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.37

Quick Ratio

0.90

Cash Ratio

0.23

Profitability

Gross Margin

59.89

Operating Margin

10.38

Pretax Margin

6.25

Net Margin

5.54

Return on Assets

1.84

Return on Equity

5.17

Return on Total Capital

5.20

Return on Invested Capital

2.87

Capital Structure

Total Debt to Total Equity

82.33

Total Debt to Total Capital

45.15

Total Debt to Total Assets

29.67

Long-Term Debt to Equity

77.97

Long-Term Debt to Total Capital

42.77

Officers and Executives

Name Age Officer Since Title
Dr. Norbert Winkeljohann 62 2018 Member-Supervisory Board
Mr. Werner Baumann 57 1988 Principal
Mr. Wolfgang U. Nickl 50 2018 Member-Management Board
Mr. Bijoy Sagar 50 2020 Chief Information Technology Officer
Ms. Marianne de Backer 50 2019 Head-Licensing Pharmaceuticals Division

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/bayry

MarketWatch News on BAYRY

  1. Bayer reports $11.2 bln loss on Roundup costs

    2:18 a.m. Aug. 4, 2020

    - MarketWatch.com

  2. Bayer loses Roundup appeal, but damages slashed

    10:50 p.m. July 20, 2020

    - MarketWatch.com

  3. Bayer shares climb after $11B roundup settlement

    4:11 a.m. June 25, 2020

    - MarketWatch.com

  4. Bayer settles Roundup lawsuits for $10.9 million

    7:07 p.m. June 24, 2020

    - MarketWatch.com

  5. Bayer reaches $10.5 billion Roundup settlement

    12:59 p.m. June 24, 2020

    - MarketWatch.com

  6. Bayer to pay up to $10.9 bln to resolve about 75% of litigation over weedkiller Roundup

    12:52 p.m. June 24, 2020

    - Tomi Kilgore

  7. Bayer rises on report of U.S. lawsuits progress

    5:23 a.m. May 25, 2020

    - MarketWatch.com

  8. Astrazeneca’s First Quarter Shows Stock Can Weather the Storm

    5:48 p.m. April 29, 2020

    - Barron's Online

  9. Syndax Pharmaceuticals Gains 57% After Cancer Conference

    5:29 p.m. April 28, 2020

    - Barron's Online

  10. Bayer backs 2020 guidance as profit rises

    2:15 a.m. April 27, 2020

    - MarketWatch.com

  11. UK regulator probes Elanco asset sale to Dechra

    2:26 a.m. April 20, 2020

    - MarketWatch.com

  12. Loading more headlines...
/news/nonmarketwatch/company/us/bayry

Other News on BAYRY

  1. Bayer Swings to Net Loss on Roundup Settlement Deal

    3:27 a.m. Aug. 4, 2020

    - Ruth Bender

  2. If It Has To Be - 4 Picks For July

    1:34 p.m. July 28, 2020

    - Seeking Alpha

  3. Wide-Moat Stocks On Sale - The August 2020 Heat Map

    10:40 a.m. July 27, 2020

    - Seeking Alpha

  4. Exelixis Starts Study on Cabometyx Combo in Kidney Cancer

    10:00 a.m. July 21, 2020

    - Zacks.com

  5. Bayer Loses Roundup Appeal

    5:18 p.m. July 20, 2020

    - Sara Randazzo

  6. AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?

    9:15 a.m. July 20, 2020

    - Zacks.com

  7. Loading more headlines...

At a Glance

Bayer AG

Kaiser-Wilhelm-Allee 1

Leverkusen, Nordrhein-Westfalen 51368

Phone

49 214301

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$43.55B

Net Income

$2.41B

2019 Sales Growth

10.0%

Employees

103,824

/news/pressrelease/company/us/bayry

Press Releases on BAYRY

  1. Connected Drug Delivery Devices Market | Regional Growth Forecast 2020-2026

    10:46 a.m. Aug. 7, 2020

    - Market Insight Reports

  2. Loading more headlines...
Link to MarketWatch's Slice.